Tracking lung cancer evolution through treatment
Part of Cancer, Lungs & breathing clinical trials.
This study follows people with lung cancer over time to see how the disease changes, especially during and after treatment. By collecting tumor samples and blood tests every few months, researchers hope to understand why some cancers come back or become resistant, and find better ways to treat them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with non-small cell lung cancer (early or advanced), small cell lung cancer, or mesothelioma.
- You need to have enough tumor tissue available for testing (either fresh or from a stored tissue block).
- You must agree to return for check-ups and sample collection every 3 months for the first 2 years, then every 6 months.
- You should be fit enough for surgery or cancer treatment (performance status 0 to 2).
- You cannot have had another active cancer (except certain skin cancers) or treatment for it in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from adults with different types and stages of lung cancer to connect molecular test results with treatment choices and outcomes. It may help improve how lung cancer is diagnosed and managed by building a better understanding of what works for different patients.
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This study looks at how lung cancer changes over time by analyzing tumor tissue and blood. It may help researchers understand what drives cancer relapse after early-stage surgery.
This trial looks at information and tissue from people with stage I to stage IIIA non-small cell lung cancer (NSCLC) who have surgery, sometimes with chemotherapy before surgery. Researchers want to understand why cancers come back (resistance) and how to better target treatments later.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.